Home › Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO
 

Keywords :   


Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO

2014-05-31 19:24:01| Logistics - Topix.net

Clovis Oncology today announced results from an ongoing Phase 1/2a monotherapy study evaluating lucitanib, the Company's novel, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 , vascular endothelial growth factor receptors 1 through 3 and platelet-derived growth factor receptors alpha and beta .

Tags: results study reports phase

Category:Transportation and Logistics

Latest from this category

All news
05.10Eastern North Pacific Tropical Weather Outlook
05.10Atlantic Tropical Weather Outlook
04.10Hurricane Kirk Graphics
04.10Hurricane Kirk Forecast Discussion Number 22
04.10Summary for Hurricane Kirk (AT2/AL122024)
04.10Hurricane Kirk Public Advisory Number 22
04.10Hurricane Kirk Wind Speed Probabilities Number 22
04.10Tropical Storm Leslie Forecast Discussion Number 10
Transportation and Logistics »
05.10Eastern North Pacific Tropical Weather Outlook
05.10Atlantic Tropical Weather Outlook
04.10Should you tip even if the service wasn't worth it?
04.10Hurricane Kirk Graphics
04.10Hurricane Kirk Forecast Discussion Number 22
04.10Tropical Storm Leslie Forecast Discussion Number 10
04.10Hurricane Kirk Wind Speed Probabilities Number 22
04.10Hurricane Kirk Public Advisory Number 22
More »